Biogen
BIIB
951 hedge funds and large institutions have $25.9B invested in Biogen in 2022 Q1 according to their latest regulatory filings, with 82 funds opening new positions, 319 increasing their positions, 389 reducing their positions, and 132 closing their positions.
9% more funds holding in top 10
Funds holding in top 10: 11 → 12 (+1)
0.55% less ownership
Funds ownership: 84.37% → 83.81% (-0.55%)
1% less call options, than puts
Call options by funds: $789M | Put options by funds: $798M
6% less funds holding
Funds holding: 1,009 → 951 (-58)
13% less capital invested
Capital invested by funds: $29.7B → $25.9B (-$3.78B)
18% less repeat investments, than reductions
Existing positions increased: 319 | Existing positions reduced: 389
38% less first-time investments, than exits
New positions opened: 82 | Existing positions closed: 132
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$158M |
| 2 |
Two Sigma Advisers
New York
|
+$140M |
| 3 |
Man Group
London,
United Kingdom
|
+$132M |
| 4 |
BlackRock
New York
|
+$86.8M |
| 5 |
D.E. Shaw & Co
New York
|
+$86.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$513M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$112M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$111M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$109M |
| 5 |
Amundi
Paris,
France
|
-$99.2M |
BIIB Hedge Fund Activity: Q1 2022 in Review
951 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q1 2022, worth a combined $25.9B — down 13% from $29.7B a quarter earlier.
Sellers outnumbered buyers: 132 funds closed out of BIIB and 82 opened new positions — a net loss of 50 holders — while 389 trimmed existing stakes and 319 added.
The largest buyer was RA Capital Management, opening a new position worth an estimated $158M. The largest seller was JP Morgan Chase, cutting an estimated $513M.
- 951 institutional investors held Biogen (BIIB) as of Q1 2022, down from 1,009 in Q4 2021.
- Funds reported $25.9B of Biogen stock for Q1 2022, down 13% quarter-over-quarter.
- 82 funds opened new Biogen positions in Q1 2022 and 132 closed out, a net change of -50 holders.
- The largest Biogen buyer in Q1 2022 was RA Capital Management, an estimated $158M added.
- The largest Biogen seller in Q1 2022 was JP Morgan Chase, an estimated $513M sold.
Based on aggregated 13F filings for Q1 2022.